Despite the discoveries of numerous agents including next generation proteasome
inhibitors, immunomodulatory drugs, and monoclonal antibodies, multiple myeloma (MM) …

Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation
of plasma cells. Although therapeutic advances have been made to improve clinical …

Mesenchymal stromal cells (MSCs) within the protective microenvironment of multiple
myeloma (MM) promote tumor growth, confer chemoresistance and support metabolic needs …

Obesity is a global pandemic that has been associated with the development of breast,
endometrial, large intestine, renal, esophageal, and pancreatic cancer. Obesity is also …

Natural Killer (NK) cells act as important regulators in the development and progression of
hematological malignancies and their suppressor activity against Multiple Myeloma (MM) …

Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that
immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively …

Multiple myeloma is a heterogeneous clonal malignant plasma cell disorder, which remains
incurable despite the therapeutic armamentarium's evolution. Bispecific antibodies (BsAbs) …

Multiple myeloma (MM) is the second most common hematological malignancy and is
attributed to monoclonal proliferation of plasma cells in the bone marrow. Cancer cells …

Bone marrow-derived mesenchymal stem cell (BMSC) is one crucial component of the
multiple myeloma (MM) microenvironment and supports the malignant progression of MM …

The success of senescence-based anticancer therapies relies on their anti-proliferative
power and on their ability to trigger anti-tumor immune responses. Indeed, genotoxic drug …